These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34854279)

  • 1. Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS.
    Bertrums EJM; Zwaan CM; Hasegawa D; De Haas V; Reinhardt DN; Locatelli F; De Moerloose B; Dworzak M; Buijs A; Smisek P; Kolenova A; Pronk CJ; Klusmann JH; Carboné A; Ferster A; Antoniou E; Meshinchi S; Raimondi SC; Niemeyer CM; Hasle H; Van den Heuvel-Eibrink MM; Goemans BF
    Haematologica; 2022 Mar; 107(3):759-764. PubMed ID: 34854279
    [No Abstract]   [Full Text] [Related]  

  • 2. Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia.
    Pourhassan H; Kim Y; Pullarkat V
    Eur J Haematol; 2023 Feb; 110(2):213-216. PubMed ID: 36335580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
    Thepot S; Itzykson R; Seegers V; Raffoux E; Quesnel B; Chait Y; Sorin L; Dreyfus F; Cluzeau T; Delaunay J; Sanhes L; Eclache V; Dartigeas C; Turlure P; Harel S; Salanoubat C; Kiladjian JJ; Fenaux P; Adès L;
    Blood; 2010 Nov; 116(19):3735-42. PubMed ID: 20664061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms.
    Kim JR; Cho YU; Bae MH; Kim B; Jang S; Seo EJ; Chi HS; Park CJ
    Ann Lab Med; 2016 Jul; 36(4):377-9. PubMed ID: 27139614
    [No Abstract]   [Full Text] [Related]  

  • 5. [Myeloproliferative disorders and leukemia related to Down syndrome. Report of two clinical cases in neonatal period].
    Castro MX; Aristizabal AM; Aristizabal C; Llanos N; Jaramillo ML
    Arch Argent Pediatr; 2022 Apr; 120(2):e89-e92. PubMed ID: 35338823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute non-lymphocytic leukaemia versus transient leukaemoid reaction in fetuses with Down syndrome.
    Gaedicke G; Kleihauer E; Terinde R
    Lancet; 1990 Apr; 335(8693):857. PubMed ID: 1969581
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recent advances of studies on the therapy-related myelodysplastic syndromes/acute myeloid leukemia].
    Li CJ; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1757-60. PubMed ID: 25543511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A newborn infant with Down syndrome and acute myeloid leukemia. Diagnostic difficulties between the malignant form and the myeloproliferative syndrome].
    Cominetti M; Rasore-Quartino A; Acutis MS; Vignola G
    Pathologica; 1985; 77(1052):625-30. PubMed ID: 2950370
    [No Abstract]   [Full Text] [Related]  

  • 9. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
    Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
    Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
    Valent P
    Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial myelodysplastic syndrome/acute myeloid leukemia.
    Churpek JE
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):287-289. PubMed ID: 29156196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal hematologic disorders in Down syndrome. A review.
    Avet-Loiseau H; Mechinaud F; Harousseau JL
    J Pediatr Hematol Oncol; 1995 Feb; 17(1):19-24. PubMed ID: 7743232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary acute myeloid leukemia - a single center experience.
    Szotkowski T; Rohon P; Zapletalova L; Sicova K; Hubacek J; Indrak K
    Neoplasma; 2010; 57(2):170-8. PubMed ID: 20099982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
    Hoyle CF; de Bastos M; Wheatley K; Sherrington PD; Fischer PJ; Rees JK; Gray R; Hayhoe FG
    Br J Haematol; 1989 May; 72(1):45-53. PubMed ID: 2736242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes.
    Kodali D; Mesa H; Rawal A; Cao Q; Gupta P
    Leuk Lymphoma; 2007 Dec; 48(12):2375-80. PubMed ID: 18067013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mixed myelodysplastic and myeloproliferative syndromes].
    Neuwirtová R; Mociková K; Jelínek J; Musilová J; Havlícek F; Adamkov M; Michalová K; Cermák J; Jonásová A; Smolíková A; Straub J; Tothová E; Voglová J; Vozobulová V; Waltrová L
    Cas Lek Cesk; 1997 Dec; 136(23):724-9. PubMed ID: 9476375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.